Ropinirole Functions Through a Dopamine Receptor D 2‐Independent Mechanism to Ameliorate Amyotrophic Lateral Sclerosis Phenotypes in TARDBP ‐Mutant i PSC ‐Derived Motor Neurons
Journal of Neurochemistry · 2025
DOI: 10.1111/jnc.70183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurochemistry, 2025. Verfasst von Hirotsugu Asano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery Research Department, K Pharma, Inc., Fujisawa-shi, Kanagawa, Japan. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Induced Pluripotent Stem Cells, Motor Neurons, Receptors, Dopamine D2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motor neuron (MN) degeneration. Ropinirole hydrochloride (ROPI), a dopamine receptor D2 (DRD2) agonist, was identified through phenotypic screening of MNs derived from patient‐derived induced pluripotent stem cells (iPSCs) as a disease model and has emerged as a promising candidate drug for ALS treatment. The ROPALS trial, a phase I/IIa trial in patients with ALS, suggested the safety and efficacy of ROPI, albeit in a small sample size. Interestingly, a DRD2 antagonist and modulator only partially mitigated the suppressive effect of ROPI on the ALS phenotype, and the detailed mechanism of ROPI activity remains unclear. Therefore, in this study, we investigated whether the therapeutic effects of ROPI in ALS are dependent on DRD2. For this purpose, we generated DRD2‐deficient iPSCs and showed that ROPI effectively reduced neuronal cell death, reactive oxygen species (ROS) production, and neuronal hyperexcitation, independently of DRD2. Further analyses revealed that ROPI corrected aberrant RNA splicing and restored the mRNA expression of mitochondrial proteins in a DRD2‐independent manner. Our findings suggest that ROPI not only functions as a canonical DRD2 agonist but also has pleiotropic DRD2‐independent effects, offering a novel avenue for treatment strategies that target multiple pathways involved in ALS pathology. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Discovery Research Department, K Pharma, Inc., Fujisawa-shi, Kanagawa, Japan.
- Keio University Regenerative Medicine Research Center, Kawasaki-shi, Kanagawa, Japan.
- Core Research Facilities for Basic Science, Research Center for Medical Science, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
- Department of Pharmaceutical Sciences, Osaka Medical and Pharmaceutical University, Takatsuki-shi, Osaka, Japan.
ORCID-Profile: Hirotsugu Asano, Tetsuya Kawaguchi, Hideyuki Okano
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
Zitieren
APA
Asano, H., Kawaguchi, T., Kato, C., Morimoto, S., Yano, M., Minaguchi, M., Yasuda, D., Fukushima, K., & Okano, H. (2025). Ropinirole Functions Through a Dopamine Receptor D 2‐Independent Mechanism to Ameliorate Amyotrophic Lateral Sclerosis Phenotypes in TARDBP ‐Mutant i PSC ‐Derived Motor Neurons. Journal of Neurochemistry. https://doi.org/10.1111/jnc.70183
Vancouver
Asano H, Kawaguchi T, Kato C, Morimoto S, Yano M, Minaguchi M, et al. Ropinirole Functions Through a Dopamine Receptor D 2‐Independent Mechanism to Ameliorate Amyotrophic Lateral Sclerosis Phenotypes in TARDBP ‐Mutant i PSC ‐Derived Motor Neurons. Journal of Neurochemistry. 2025. doi:10.1111/jnc.70183
BibTeX
@article{Asano2025,
author = {Asano, Hirotsugu and Kawaguchi, Tetsuya and Kato, Chris and Morimoto, Satoru and Yano, Masato and Minaguchi, Maki and Yasuda, Daisuke and Fukushima, Komei and Okano, Hideyuki},
title = {Ropinirole Functions Through a Dopamine Receptor D 2‐Independent Mechanism to Ameliorate Amyotrophic Lateral Sclerosis Phenotypes in TARDBP ‐Mutant i PSC ‐Derived Motor Neurons},
journal = {Journal of Neurochemistry},
year = {2025},
doi = {10.1111/jnc.70183}
}
EUVIMED